None listed
Conditions
Interventions
Trade Name: Yondelis 0,25 mg powder for concentrate for solution for infusion
Product Name: YONDELIS (Trabectedin)
Product Code: ET-743
Pharmaceutical Form: Powder for concentrate for solution for inf
Sponsors
Pharma Mar, S.A.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Men or women between 18 and 65 years of age, inclusive 2. Subjects with locally advanced or metastatic solid tumors who have received three or less prior lines of systemic chemotherapy will be included. 3. Subjects must have relapsed or had progressive disease following standard of care treatment with chemotherapy prior to enrollment, or intolerant to prior standard of care treatment with chemotherapy 4. Subjects who have had total prior anthracycline over 260 mg/m2 should have LVEF within normal limits, according to the institutional guidelines. A MUGA (multigated acquisition) scan or 2-d echocardiogram must be performed within 6 weeks before enrollment. 5. Blood pressure (after the subject is supine for 10 minutes) between 90 and 140 mmHg systolic, inclusive, and no higher than 90 mmHg diastolic 6. A 12-lead ECG consistent with normal cardiac conduction and function, showing: · Sinus rhythm · Pulse rate between 45 and 90 bpm · QTc interval ULN, measure indirect bilirubin to rule out Gilbert's syndrome (if indirect bilirubin is within normal range, subject is eligible) – total alkaline phosphatase (ALP) 1.5 ULN, ALP liver fraction or 5’ nucleotidase must be < or = ULN – AST and ALT must be < or = 2.5 x ULN 11. Adequate recovery from surgery, at least 2 weeks from last dose of hormonal therapy, at least 3 weeks from prior chemo- or biological therapy, at least 3 weeks from receiving radiotherapy, at least 4 weeks after or a period 10 times the drug’s half life (approximately 75 days), whichever is longer, before the first dose of the study drug is scheduled from the last experimental anticancer therapy, and 6 weeks in the case of receipt of nitrosoureas or mitomycin C, provided all side effects from these therapies have resolved to grade 1 or less according to the National Cancer Institute – Common Terminology Criteria of Adverse Events (NCI_CTCAE, Version 3) 12. Must be able to receive dexamethasone or its equivalent 13. If female, must be postmenopausal (no spontaneous menses for at least 2 years), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study 14. If female of child bearing potential, must have a negative serum ß-human chorionic gonadotropin (ß-hCG)] pregnancy test at screening; and a negative urine pregnancy test on Day –1 of the treatment phase 15. If male, must agree to use an adequat
Exclusion criteria
Exclusion criteria: 1. Subjects treated with more than three prior chemotherapy regimens (including adjuvant therapy) 2. Previous exposure to trabectedin 3. Subjects with CNS metastasis 4. Known hypersensitivity to any of the components of the trabectedin i.v. formulation or dexamethasone 5. Have heart rhythm disturbances, unusual T wave and U wave (if present) morphology, blood pressure outside of normal range, a history of cardiac failure, myocardial infarction, or cardiomyopathy, or a history of additional risk factors for torsade de pointes (e.g. heart failure, electrolyte abnormalities, family history of Long QT Syndrome) 6. Have any skin condition likely to interfere with ECG electrode placement, a history of breast implant or thoracic surgery likely to cause abnormality in electrical conduction 7. Subjects who at screening are on medication (refer to Attachment 5) that is known to prolong the QT interval or who are on CYP3A4 inhibitors or inducers. Subjects must have been off these medications for a mimumum of 5 half-lives. 8. History of or current clinically significant medical illness including (but not limited to), congestive heart failure, angina pectoris, or other cardiac disease, uncontrolled hypertension or uncontrolled arrhythmia, symptomatic brain metastases or leptomeningeal disease, significant pulmonary disease, including bronchospastic respiratory disease, uncontrolled diabetes, renal or hepatic insufficiency, thyroid disease, neurologic or psychiatric disease, infection, positive serology results for hepatitis B surface antigen (HBsAg), or hepatitis C antibodies, or any other illness that the investigator considers should exclude the subject or that could interfere with the interpretation of the study results 9. Subjects unwilling or unable to have a central catheter 10. History of illegal drug use or alcohol abuse within 6 months before study drug administration 11. If a woman, breast-feeding or planning to become pregnant during the study 12. Preplanned surgery or procedures that would interfere with the conduct of the study 13. Employee of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The objective of this study is to assess the potential effects of trabectedin on the QT/QTc interval duration measured by electrocardiograms (ECGs) in subjects with advanced solid tumor malignancies when administered at a therapeutic dose. ;Secondary Objective: The secondary objectives of this study are to assess the survival, the safety and pharmacokinetics of trabectedin.;Primary end point(s): The primary pharmacodynamic endpoint will be the difference in delta-QTc at each scheduled time point. | — |
Countries
Belgium, France
Outcome results
None listed